DEFINITIVE Trial Milestone: 50% Recruitment Achieved

Key Takeaways

• Business Wire (6 May 2026): all centres approved; >50% of 304-patient target recruited across 33 open sites in 7 countries.
• Registry ID NCT06446882; sponsor Fundacio Clinic Barcelona; Phase III randomised open-label design.
• Population: stage II–IIIA HER2-positive breast cancer suitable for neoadjuvant therapy.
• Primary aim: show HER2DX-guided management improves quality of life/safety/cost outcomes without sacrificing efficacy versus local standard guidance.

What milestone did DEFINITIVE announce?

On 6 May 2026, project partners stated via Business Wire that approvals are in place in seven countries, 33 clinical sites are open, and enrolment has exceeded 50% of the 304-patient target.

What is the trial design?

ClinicalTrials.gov NCT06446882 describes an international, multicentre, prospective, randomised, two-arm, open-label Phase III study evaluating HRQoL, safety, efficacy, and costs of using HER2DX in stage II–IIIA HER2-positive breast cancer suitable for neoadjuvant therapy.

• Enrolment target: 304
• Start: 11 Oct 2024
• Est. completion: Nov 2028

How are patients assigned?

Patients are randomised to HER2DX-guided treatment versus standard physician-led local guidelines, enabling comparison of tumour response, quality of life, safety, and cost-effectiveness.

Why does 50% recruitment matter for oncology BD?

Crossing halfway with all centres open reduces operational risk for an EU-funded diagnostics-guided interventional trial and keeps the study on its stated recruitment schedule heading into later readout windows.

What remains unproven?

A recruitment milestone is not an efficacy result. HER2DX clinical utility versus standard guidance will be judged only after primary analyses; do not infer outcome superiority from enrolment pace.

Where can teams verify status?

Use ClinicalTrials.gov NCT06446882 for site and status updates, and the May 2026 Business Wire release for the 50% recruitment claim timed to ESMO Breast 2026.

Which countries and sites are active?

The May 2026 Business Wire update cites approvals across seven participating countries and 33 open recruiting centres, with recruitment in Israel already completed. Earlier project materials described a network of up to 44 hospitals in European and associated countries under EU funding.

Operationally, converting site approvals into sustained enrolment above the halfway mark is the near-term execution risk. ClinicalTrials.gov remains the registry of record for status changes, while the Business Wire note timestamps the 50% claim for ESMO Breast 2026 communications.

Business development teams watching HER2-positive early breast cancer diagnostics should treat DEFINITIVE as a prospective utility trial, not a retrospective assay marketing study, until primary HRQoL and efficacy analyses read out.

What endpoints will decide clinical utility?

Registry materials emphasise health-related quality of life, safety, efficacy, and economic costs as co-equal evaluation domains. That mix matters for payers and guideline committees that will not accept assay-guided de-escalation without evidence that survival-linked endpoints remain intact.

Until those analyses mature, the only verified claims are operational: NCT06446882 is recruiting, the May 2026 wire documents more than 50% of 304 patients enrolled, and 33 centres across seven countries are open. Keep efficacy language out of BD decks until primary results publish.

Related NovaPharma coverage

• Camizestrant CHMP opinion
• Imfinzi MIBC EU approval
• EMA Management Board March 2026

Frequently Asked Questions

Primary Sources

1. Business Wire: DEFINITIVE 50% recruitment milestone
2. ClinicalTrials.gov NCT06446882
3. Business Wire: DEFINITIVE project launch announcement